Medical isotope developer IsoRay has closed its final round of angel and private capital fundraising, according to the Richland, WA-based firm.
IsoRay said it has raised more than $10 million in debt and equity over the past 18 months through a private offering. It said it is planning to raise its next round of funding through institutional and public sectors in October.
In other news, the firm said its cesium-131 low-dose radiation (LDR) seed brachytherapy product will be offered at Warren General Hospital in Warren, PA.
By AuntMinnie.com staff writers
June 28, 2005
Related Reading
IsoRay implants first cesium-131 seed, October 27, 2004
IsoRay inks deal with PNNL and U.S. DOE, May 11, 2004
Copyright © 2005 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
